CLINICAL LASERTHERMIA SYSTEMS AB Clinical Laserthermia Systems AB (publ) announced that a publication with the title Preclinical assessment of a non-cooled MR thermometry-based neurosurgical laser therapy system has been published in the well renowned Journal of Neurosurgery. The research presented was conducted by CLS and partner ClearPoint Neuro Inc., with neurosurgeon Dr. John Rolston, MD, PhD leading the study as Principal Investigator. An animal model was used to demonstrate the safety, accuracy, and efficacy of the neuro laser therapy system including MR thermometry software developed and manufactured by CLS.
Commercialization and design input are ongoing by ClearPoint, using the brand name ClearPoint Prism. The results were achieved by demonstrating safe and highly efficient use of CLS TRANBERG non-cooled laser applicators in porcine brain. The laser light caused thermal damage in the target tissue leading to coagulative necrosis and finally to cell death.
Thermoguide thermometry software estimated the thermal damage and provided color-coded Thermal Damage Thresholds that predicted irreversible tissue damage, and clearly delineated safety margins to eloquent brain structures. Additional results were achieved by evaluating the accuracy of temperature prediction by Thermoguide compared to calibrated temperature probes in vivo, and by histology of the brain tissue after 3 days survival. The authors conclude that Thermoguide provided an accurate near-real-time temperature map of the brain tissue, demonstrated by high correlation between Thermoguide thermometry and physical temperature probes.
Dimensions and location of the irreversible tissue damage estimate, as visualized by the software, agreed well with histopathology. Currently, a CLS-sponsored clinical study is ongoing at Skåne University Hospital, Lund, Sweden. The Prism system is in limited market release at selected academic medical centers across the United States.
